Search

Your search keyword '"Omosa-Manyonyi, Gloria"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Omosa-Manyonyi, Gloria" Remove constraint Author: "Omosa-Manyonyi, Gloria"
41 results on '"Omosa-Manyonyi, Gloria"'

Search Results

2. Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda

3. Plasma Inflammatory Proteome Profile in a Cohort of Patients with Recurrent Vulvovaginal Candidiasis in Kenya.

4. PA-512 Behavioural predictors of uptake of HIV and pregnancy prevention products among adolescent girls and young women and female sex workers in Kenya and Uganda

5. Establishment and implementation of a regional mucosal training program to facilitate multi-center collaboration in basic and clinical research in Eastern Africa

6. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

13. sj-doc-1-jmh-10.1177_15579883221106331 – Supplemental material for Attitudes Toward Gender-Based Violence Among Sexually Active Adult Men at High Risk for HIV in Rustenburg, South Africa

14. sj-pdf-1-std-10.1177_09564624221087533 – Supplemental Material for Inadequacies in service delivery for the diagnosis and treatment of vaginitis and vaginosis in Nairobi, Kenya

15. Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa

16. Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support of HIV vaccine clinical trials

17. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity

18. Willingness to participate in future HIV vaccine trials among men who have sex with men and female sex workers living in Nairobi, Kenya

21. Performance of an IAVI-African Network of Clinical Research Laboratories in Standardized ELISpot and Peripheral Blood Mononuclear Cell Processing in Support of HIV Vaccine Clinical Trials

23. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus–Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens

24. Assessment of Anti–HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations

26. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults

27. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.

28. Acceptability and Feasibility of Repeated Mucosal Specimen Collection in Clinical Trial Participants in Kenya

29. Assessment of Viral Inhibition Activity in Low Seroprevalent Adenovirus-35 Vectored HIV Vaccines+/− Adjuvanted Protein or Electroporated DNA

30. Major Negative Social Impacts Are Rare in Phase 1 HIV Vaccine Trials in Africa

31. Implementation of a Training Program to Standardize Mucosal Sample Collection and Processing at Multiple Laboratories in Eastern Africa

32. Detection of Vaccine Induced Mucosal Antibodies in Phase I HIV Preventative Vaccine Trials

33. Overweight BMI and Alcohol Use Are Associated with Immune Responses in Phase I HIV Vaccine Trials

34. Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa

35. Reasons for Ineligibility in Phase 1 and 2A HIV Vaccine Clinical Trials at Kenya Aids Vaccine Initiative (KAVI), Kenya

36. Safety and Immunogenicity Study of Multiclade HIV-1 Adenoviral Vector Vaccine Alone or as Boost following a Multiclade HIV-1 DNA Vaccine in Africa

37. Afri-Can Forum 2

38. Overweight BMI and Alcohol Use Are Associated with Immune Responses in Phase I HIV Vaccine Trials.

39. Major Negative Social Impacts Are Rare in Phase 1 HIV Vaccine Trials in Africa.

40. Detection of Vaccine Induced Mucosal Antibodies in Phase I HIV Preventative Vaccine Trials.

41. Assessment of Anti-HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations.

Catalog

Books, media, physical & digital resources